Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Aethlon Medical (AEMD)

Aethlon Medical (AEMD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Aethlon Medical 9635 GRANITE RIDGE DRIVE SUITE 100 SAN DIEGO CA 92123 USA

P: 858-459-7800 F: 858-272-2738

Description:

Aethlon Medical, Inc. is a development stage medical device company focused on expanding the applications of our Hemopurifier (R) platform technology, which is designed to rapidly reduce the presence of infectious viruses and other toxins from human blood. In this regard, its core focus is the development of therapeutic devices that treat acute viral conditions, chronic viral diseases and pathogens targeted as potential biological warfare agents. The Hemopurifier(R) combines the established scientific principles of affinity chromatography and hemodialysis as a means to mimic the immune system's response of clearing viruses and toxins from the blood before cell and organ infection can occur. The Hemopurifier(R) cannot cure viral conditions but can prevent virus and toxins from infecting unaffected tissues and cells. The company has completed pre-clinical blood testing of the Hemopurifier(R) to treat HIV and Hepatitis-C, and have completed human safety trials on Hepatitis-C infected patients in India.

Key Statistics

Overview:

Market Capitalization, $K 53,082
Shares Outstanding, K 15,386
Annual Sales, $ 660 K
Annual Net Income, $ -7,890 K
Last Quarter Sales, $ 130 K
Last Quarter Net Income, $ -2,100 K
60-Month Beta 0.57
% of Insider Shareholders 1.17%
% of Institutional Shareholders 5.53%
Float, K 15,206
% Float 98.83%

Growth:

1-Year Return 130.77%
3-Year Return -77.45%
5-Year Return -95.21%
5-Year Revenue Growth -25.84%
5-Year Earnings Growth 93.43%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 10/27/21
Earnings Per Share ttm -0.66
EPS Growth vs. Prev Qtr -6.67%
EPS Growth vs. Prev Year -6.67%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-15 on 10/15/19

AEMD Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward -4.37
Price/Earnings to Growth N/A
Return-on-Equity % -58.10%
Return-on-Assets % -53.37%
Profit Margin % -1,195.45
Net Margin % N/A
Debt/Equity 0.00
Price/Sales 81.72
Price/Cash Flow N/A
Price/Book 2.29
Book Value/Share 1.61
Interest Coverage 0.00
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar